Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants.

In 30 seconds

This Phase 1 open-label crossover study evaluated the effects of ecnoglutide on the pharmacokinetics of rosuvastatin and digoxin in 28 healthy adults. The results indicated that ecnoglutide did not significantly alter the pharmacokinetics of either drug, with geometric mean ratios of 106% for rosuvastatin and 84% for digoxin. No dose adjustments are necessary for co-administration.

Key findings

• Ecnoglutide did not significantly affect the pharmacokinetics of rosuvastatin (GM ratio 106%, 90% CI 94%-120%).
• Digoxin's maximum plasma concentration decreased from 1.39 to 1.31 ng/mL but remained within the therapeutic window.
• The most common adverse events included weight loss and gastrointestinal issues, consistent with GLP-1 effects.
• Ecnoglutide treatment resulted in a mean body weight reduction of 11.2% over 14 weeks.

Why it matters

Understanding drug interactions is crucial for safe prescribing practices. This study provides evidence that ecnoglutide can be safely co-administered with rosuvastatin and digoxin without requiring dose adjustments, which is important for managing patients on these medications.